- In a population pharmacokinetic analysis of TREANDA® in patients receiving 120 mg/m2 there was no meaningful effect of renal impairment (CrCL 40-80 mL/min, N=31) on the pharmacokinetics of TREANDA
- Bendamustine has not been studied in patients with CrCL <40 mL/min
- No formal studies assessing the impact of renal impairment on the pharmacokinetics of TREANDA have been conducted
- In preclinical studies, approximately 90% of TREANDA administered was recovered primarily in the feces
Back to top
ULN = upper limit of normal; AST = aspartate aminotransferase; ALP = alkaline phosphatase; ALT = alanine aminotransferase.
- In a population pharmacokinetic analysis of TREANDA in patients receiving 120 mg/m2 there was no meaningful effect of mild (total bilirubin ≤ ULN, AST ≥ ULN to 2.5 x ULN, and/or ALP ≥ ULN to 5.0 x ULN, N=26) hepatic impairment on the pharmacokinetics of TREANDA
- Bendamustine has not been studied in patients with moderate or severe hepatic impairment
- No formal studies assessing the impact of hepatic impairment on the parmacokinetics of TREANDA have been conducted
Back to top
- Women should be advised to avoid becoming pregnant throughout treatment and for 3 months after TREANDA therapy has stopped
- Men receiving TREANDA should use reliable contraception throughout treatment and for 3 months after TREANDA therapy has stopped
- If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus
- Advise patients to report pregnancy immediately
- Advise patients to avoid nursing
Back to top
- Nursing mothers
Advise patients to avoid nursing while taking TREANDA. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants and tumorigenicity shown for TREANDA in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
- Pediatric use
The safety and effectiveness of TREANDA in pediatric patients have not been established.
- Geriatric use
There were no clinically significant differences in adverse reactions between geriatric (≥65 years of age) and younger patients.
- Effect of gender
No clinically significant differences between genders were seen in the overall incidences of adverse reactions.
Back to top
TREANDA for injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. TREANDA is also indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.
The following serious adverse reactions have been associated with TREANDA: myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation. Some of these reactions have been fatal, including myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN). Patients should be monitored closely for these reactions and treated promptly if any occur. Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment. Myelosuppression is frequently severe and should be expected when treating patients with TREANDA.
TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA.
The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.
Please see full Prescribing Information.